PARP1 and familial pancreatic carcinoma: As additional controls, the indicated pancreatic cancer cells were treated with ABT-888, a poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor [69], or MK-1775, a Wee1 kinase inhibitor [70] and then exposed to IR.